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T win studies assume exceptional relevance when we aim to analyze the brain pathologies associated with a diagnosis of Alzheimer disease (AD). It is now clear that multiple brain pathologies frequently co-occur in the same aged individual, 1 showing different levels of severity and anatomic distribution, and that cannot be linearly correlated with the specific cognitive manifestations observed in a single AD patient. 2 Even monozygotic (MZ) twins within a pair can show different degrees of clinicopathologic variability. [3] [4] [5] If we could assess autopsy-brains from clinically well characterized MZ and dizygotic (DZ) twins with or without dementia, and deceased during the same year, the epidemiological, clinical, pathologic, genetic, and molecular findings that could derive from these assessments would be potentially impressive. Although obtaining both brains from temporally synchronized MZ and DZ twins, that is twins deceased at the same age and that received a brain autopsy, are events more unique than rare, we had such a chance.
We report cognitive diagnoses, neuropathologic findings, and semiquantitative immunohistochemistry-based measurements of a series of co-occurring pathologies found in multiple regions of the brain of 2 twin pairs, 1 identical (MZ) and 1 fraternal (DZ), deceased at the same age. The age at death for the older male MZ pair was 98 years; the age at death for the younger opposite sex DZ pair was 79 years. With respect to ApoE genotype, where the allele ApoE4 is the major genetic risk factor for AD known so far, 6 the MZ twins were heterozygotes for the ApoE2 allele (ApoE2/3), whereas the DZ twins were both heterozygotes for the ApoE4 allele (ApoE3/4). The MZ twins were then heterozygotes for the rarest ApoE allele, the ApoE2, which is also known to have protective properties against AD. 7 The aim of the study was to assess and report semiquantitative neuropathologic findings of co-occurring brain pathologies in these 2 temporally synchronized-at death, MZ and DZ twin pairs.
MATERIALS AND METHODS
Both pairs of twins were initially part of the Swedish Twin Registry (STR). 8 STR represents one of the oldest and largest twin registries available in the world. For a more detailed description of STR and its derivative studies, refer to previous publications. 9 Selection criteria for this investigation were: (a) brain autopsy for both twins of the same pair; (b) one or both twins of the same pair diagnosed with dementia; (c) death of both twins occurred during the same year. Among a total of 140 individual twin autopsies available, only 2 twin pairs met the above criteria. 11 reflecting the year in which diagnoses were made. AD diagnoses were also reviewed accordingly to National Institute of Aging-Alzheimer's Association (NIA-AA) clinical criteria. 12 Furthermore, psychiatric symptoms were evaluated using the Neuropsychiatric Inventory for dementia. 13 Neuropathologic Criteria, Brain Regions, Immunostains, Semiquantitative Scorings All 4 brains were stored and examined for standard neuropathologic assessments at the Brain Bank at Karolinska Institutet, Karolinska University Hospital at Huddinge, Stockholm, Sweden. Each autopsy was obtained in accordance with Swedish law. A detailed description of the methods, criteria, and antibodies used to assess these twin brains has been previously described. 14 The following brain regions were selected for semiquantitative assessments of each brain: middle frontal gyrus, medial temporal gyrus, anterior cingulate gyrus, posterior hippocampus (at the level of the corpus geniculate lateral), amygdala, mesencephalon (including the substantia nigra), and pons (including the locus coeruleus).
Clinical and Cognitive Diagnosis
The following pathologic lesions were considered: b-amyloid diffuse plaques, neuritic plaques, and cored plaques (Ab-DP, Ab-NP, Ab-CP); hyperphosphorylatedtau tangles (tau-NFT), tau-threads (tau-th), tau-dystrophic neurites (tau-N), and tau-plaques (tau-P); a-synuclein positive Lewy Body (LB), and a-synuclein positive dystrophic neurites (LN); ubiquitin-positive (ubiq) neuronal cytoplasmatic inclusions (ubiq-NCI), ubiq-neuropil threads (ubiq-th), and ubiq-dystrophic neurites (ubiq-N); protein p62-positive (p62) neuronal cytoplasmatic inclusions (p62-NCI), p62-neuropil threads (p62-th), and p62-dystrophic neurites (p62-N); TDP-43-positive (TDP-43) neuronal cytoplasmatic inclusions (TDP-43-NCI), TDP-43-neuropil threads (TDP-43-th), and TDP-43-dystrophic neurites (TDP-43-N); phosphorylated-TDP-43 (pTDP-43-NCI), pTDP-43-neuropil threads (pTDP-43-th), and pTDP-43dystrophic neurites (pTDP-43-N). As for pathologic criteria, each brain was evaluated using the "practical approach" of NIA-AA pathologic criteria for AD. 15 The semiquantitative system used was defined as: no lesions = negative (N), 1-2 lesions = sparse (S), 2 to 6 lesions = moderate (M), and >6 lesions = frequent (F). For NCIs, number of lesions were referred to the number of neurons containing at least 1 cytoplasmatic inclusion independently on its shape (i.e., spheroidal or lentiform). For statistical purposes, the frequency-based semiquantitative system was transformed in a numerical system with N = 0, S = 1, M = 2, F = 3.
Descriptive Statistics
After transformation to numerical values (0 to 3) for each brain region and immunostain, all lesions were aggregated per type of pathology:
b Neuropil threads (th) and dystrophic neurites (N) TDP-43 and pTDP-43 pathology were also evaluated separately to determine possible different pTDP-43 pathology subtypes as previously proposed. 16 Cumulative scores (sum of all single numerical scores obtained for each brain region and for each immunostain) are shown in Figure 1 . 
RESULTS
Main demographic, zygosity, attained years of education, clinical diagnoses, age of dementia onset, interval between dementia onset and death, and neuropsychiatric findings are summarized in Table 1 . Autopsy-confirmed diagnoses (Consortium to Establish a Registry for Alzheimer's disease criteria) 11 were: probable AD (prob AD) for twin A1 and twin A2, and definite AD (def AD) for twin B1 and twin B2. None of the twins presented clinical or autopsy diagnosis of: Parkinson's disease, Dementia with Lewy Bodies, Vascular Dementia, PD with Dementia, or Fronto-Temporal Dementia. Levels of AD neuropathologic change (NIA-AA pathologic criteria based) were "intermediate" for all 4 twins. All twins presented psychiatric symptoms (Table 1) .
For the ApoE2/3 MZ pair, the intrapair difference between twins' ages at dementia onset was 7 years. Both twins showed marked TDP-43 and pTDP-43 pathology, defined as TDP-43 pathology of type D, 16 with greater pathology in the twin with earlier onset. The twin with later onset (and shorter survival with dementia) showed greater tau pathology in particular, but also a higher b-amyloid cumulative score compared with his twin brother. Other cooccurring pathologies were minimal. For the ApoE3/4 DZ pair, there was marked b-amyloid and tau pathology in both twins, with both cumulative scores higher in the twin with the slightly later onset, as well as substantial cooccurring brain pathologies, ubiq in particular. In contrast, there was very little TDP-43 and pTDP-43 pathology in either DZ twin. As for the anatomic distribution, only cerebral regions were constantly positive to both TDP-43 and pTDP-43 pathologies, as for other pathologies (i.e., p62, ubiq), were posterior hippocampus and amygdala. Figure 1 shows time-scales, cognition-deaths intervals, and cumulative scores-histograms, for all pathologies in both the twin pairs. Tables 2a, b, c (Supplemental Digital Content 1, http://links.lww.com/WAD/A117) (supplementary material) show single pathologic score for all types of pathology in each cerebral region considered in this study.
DISCUSSION
To the best of our knowledge, clinicopathologic correlations with semiquantitative immunohistochemistrybased neuropathologic analyses on twins deceased at the same age has never been described before.
Our autopsy findings from this unique set of same-age twin brains confirm previous larger studies supporting ApoE4 as an accelerating factor and ApoE2 as protective factor for AD. 7 ApoE2 was associated indeed with dementia, but at a quite advanced age. At the same time, in the MZ twin pair, the interval between dementia onsets suggests that other modifying factors should be taken into account 17 to better explain why their dementia onsets and clinical manifestations differed within the twin pair. Dementia in both MZ twins was associated with relatively low levels of amyloid, tau, and all other considered co-occurring brain pathologies, except for pTDP-43 pathology, with frequent NCI among diffuse TDP-43/pTDP-43-positive nuclei in both members of the pair. As novelty, this last observation suggests a possible correlation between TDP-43 pathology and duration of disease. Intriguingly, a possible new modifying effect (protective) of ApoE2 on TDP-43 pathology in very old subjects could be hypothesized based on these novel clinicopathologic observations. This possible correlation between TDP-43 pathology and duration of disease in very old subjects could acquire higher relevance considering the discrepancy between duration of disease and other "classic" AD pathologies, like tau pathology, for example.
The association of ApoE2 with reduced amounts of various brain pathologies: b-amyloid, tau, LB, ubiq, and p62 pathology is coherent with previous neuropathologic observations on the relationship between ApoE2 versus ApoE4 allele and AD pathology, especially for amyloid. 18 The TDP-43 and pTDP-43 findings may indicate differential positivity at different stages of disease, which could be also related to the ageing per se and not necessarily to a clinical form of Fronto-Temporal Dementia. Studies on TDP-43/pTDP-43 lesions, their anatomic distributions, age-related accumulations, and possible correlations to ageing-related neurodegenerative processes are largely missing. 19 Relatively less accumulation of TDP-43/pTDP-43 pathology was seen in the other twin pair, who were ApoE4 heterozygotes and had a younger age of onset. On the basis of these rare twin cases, and with the limitation of the sample size, a differential TDP-43/pTDP-43 nuclear/NCI distribution pattern in AD, and in other neurodegenerative diseases as well, could be hypothesized. This new possible clinicopathologic correlation (TDP-43 vs. duration of disease) needs to be confirmed by larger clinicopathologic studies. These studies, however, should take into account the following: the possible correlation between TDP-43 pathology accumulation and aging per se, the preferential deposition of TPD-43 pathology in specific brain regions, other co-occurring age-related brain pathologies, as well as possible modifying factors such as ApoE2 and other biological or environmental factors, which still remain unknown.
These clinicopathologic findings on age-matched-at autopsy twins provide a rare and unusual example of the complexity of AD. Although genetic factors, especially ApoE genotype, may play an important accelerating role in the pathogenesis of dementia, and specifically for AD, other nongenetic factors are necessarily involved to explain the clinicopathologic variability observed among AD cases, even between identical twins with a genetic protective factor as ApoE2.
We cannot assume that these single pairs of MZ and DZ twins are representative of MZ and DZ twins in general, but together, these 4 cases offer a unique natural experiment and a rare investigative window into the variability of brain pathologies associated with AD.
